ID   HeyA8-MDR
AC   CVCL_8879
SY   HEYA8MDR
DR   cancercelllines; CVCL_8879
DR   Wikidata; Q54883220
RX   PubMed=16951177;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8878 ! HEY A8
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=16951177; DOI=10.1158/0008-5472.CAN-06-1410;
RA   Han L.Y., Landen C.N., Trevino J.G., Halder J., Lin Y.G., Kamat A.A.,
RA   Kim T.-J., Merritt W.M., Coleman R.L., Gershenson D.M.,
RA   Shakespeare W.C., Wang Y.-H., Sundaramoorth R., Metcalf C.A. III,
RA   Dalgarno D.C., Sawyer T.K., Gallick G.E., Sood A.K.;
RT   "Antiangiogenic and antitumor effects of SRC inhibition in ovarian
RT   carcinoma.";
RL   Cancer Res. 66:8633-8639(2006).
//